Widgetized Section

Go to Admin » Appearance » Widgets » and move Gabfire Widget: Social into that MastheadOverlay zone

Repatha® (Evolocumab) Demonstrates Reduced Need For Apheresis In Patients With High LDL Cholesterol In Phase 3 Study

Published Monday March 13

Study Meets Primary and All Secondary Endpoints

…evolocumab in patients who were receiving apheresis to reduce low-density lipoprotein cholesterol. The study met its primary endpoint, demonstrating that treatment with Repatha significantly reduced the need for LDL-C apheresis in adult patients, as measured at the end of the randomized period.

Article length: About 2290 words.
Tags: Patented Acquired Purchased Sale
Read more at Prnewswire